BioSpace News Archive

Orange Orchid Research files open, provisional patent on SARS-CoV-2/COVID-19 treatment with the United States Patent and Trademark Office (USPTO).

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Morgan Stanley 18th Annual Global Healthcare Conference on Wednesday, September 16th, 2020 at 2:00 p.m. Eastern Time.

Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference.

Quotient Limited, a commercial-stage diagnostics company, announced the Company intends to commence an underwritten public offering of $60 million of its ordinary shares.

New four-week COVID-19 case projections released by PolicyLab at Children’s Hospital of Philadelphia suggest some outbreaks on college campuses will lead to increased community spread, while other schools will be likely to contain transmission.

Alkermes plc (Nasdaq: ALKS) announced today that that its Chief Executive Officer, Richard Pops, will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on Wednesday, Sept. 16, 2020 at 10:40 a.m. ET (3:40 p.m. BST)

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced further STRO-002 updated interim Phase 1 safety and preliminary efficacy data in ovarian cancer,

TherapeuticsMD Announces Patent Updates for ANNOVERA ® New patents expand U.S. patent protection for ANNOVERA BOCA RATON, Fla.--( BUSINESS WIRE )-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced patent updates for ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system), the first and only long-lasting, patient-controlled, procedure-free, reversible prescription contraceptive option for women

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Fitzgerald Virtual Global Healthcare Conference on Tuesday, September 15, 2020 at 4:40 p.m. ET / 1:40 p.m. PT. A live webcast will be available under “Events & Presentations” in

Acquisition Launches NovAccess Shift, Focusing on Diagnostics and Therapeutics in Cancer